Moleculin’s MIRACLE Data: Competitive 37% CRc Rate is Undermined by Blinded, Single-Arm Design

Moleculin Reports Positive Interim MIRACLE Trial Results in r/r AML

Moleculin Biotech announced preliminary blinded data from Part A of its pivotal Phase II/III MIRACLE trial, evaluating Annamycin combined with cytarabine (AnnAraC) in 62 adult patients with relapsed or refractory acute myeloid leukaemia (r/r AML). The study reported a complete remission (CR) rate of 24% and a composite complete remission (CRc) rate of 37%. Notably, among 30 patients who had previously failed venetoclax-based regimens, where published salvage remission rates are approximately 13%, the current blinded results are considered promising. The company anticipates concluding Part A treatment in September 2026, with comprehensive unblinded results expected between December 2026 and February 2027. The trial continues to show no evidence of cardiotoxicity, a key differentiator from conventional anthracyclines.

• The blinded Part A data from the MIRACLE trial in 62 evaluable relapsed or refractory AML patients demonstrated a complete remission (CR) rate of 24% and a composite complete remission (CRc) rate of 37% for Annamycin combined with cytarabine. These preliminary figures provide an early indication of the treatment's potential efficacy in this challenging patient population.
• A significant portion of the patient cohort (30 subjects) had previously failed first-line venetoclax-based regimens, a group typically associated with a published salvage remission rate of about 13% and a median survival of 2.4 months. The current blinded results, despite including control-arm subjects, held in a narrow band, suggesting potential benefit in this difficult-to-treat population.
• Annamycin continues to exhibit a favorable safety profile, with no observed evidence of cardiotoxicity based on reported ejection fractions and adverse events. This characteristic is a crucial differentiator from conventional anthracyclines, which are often associated with cardiac side effects, potentially offering a safer treatment option for AML patients.
• The MIRACLE trial has enrolled 74 out of a planned 90 subjects for Part A. Moleculin Biotech expects to complete Part A treatment in September 2026, with comprehensive unblinded results anticipated to be released between December 2026 and February 2027, providing a clearer picture of the drug's efficacy and safety.

Addressing the Critical Unmet Need in Relapsed/Refractory AML

Relapsed/refractory (R/R) AML remains one of the most challenging areas in hematologic oncology, with poor prognosis, high relapse rates, and limited durable treatment options continuing to define the clinical landscape over the past three years. Literature from 2022–2025 highlights persistent gaps across specific patient subgroups, resistance mechanisms, and the immunotherapeutic pipeline, even as targeted agents have reshaped frontline and relapsed treatment paradigms.

• Relapse remains the dominant clinical challenge, occurring in 40–50% of younger patients and the majority of elderly patients; even those achieving complete remission with initial therapy face high rates of subsequent relapse, driven in part by resistance to classical cell death programs (e.g., Nrf2-ALDH2/PolG2 pathway activation, compensatory mitochondrial respiration, and metabolic adaptations such as elevated ALDH2 expression).

• TP53-mutated AML represents a particularly refractory subset, with patients showing near-universal resistance to chemotherapy, molecularly targeted therapies, and allogeneic HSCT. While hypomethylating-agent/venetoclax regimens improve initial response rates, remissions are short-lived and overall survival remains poor; no optimal treatment regimen has been established, and emerging data implicate TP53 mutations in immune cells (T and NK cells) as a novel driver of immune escape, with mutant T cells showing reduced cytotoxicity and increased expression of inhibitory receptors (PD-1, TIGIT, TIM-3).

• Older adults and transplant-ineligible patients continue to experience disproportionately poor outcomes with traditional high-dose chemotherapy, underscoring the need for alternative, better-tolerated approaches, including oral targeted agents and immunotherapy-based strategies.

• Immune evasion and an immunosuppressive tumor microenvironment limit immunotherapy efficacy and contribute directly to relapse and refractoriness; AML also faces a comparative lack of suitable immunotherapeutic surface targets relative to other hematologic malignancies, complicating CAR-T and TCR-T development.

• No cellular therapy product has yet achieved regulatory approval in AML, despite active clinical evaluation of CAR-T constructs targeting CD33, CD123, and CLL-1, and TCR-T approaches directed at intracellular antigens such as WT1; adoptive cell therapies show early promise but require improved target selection.

• Pediatric R/R AML has emerged as a distinct focus area, with VISTA, CD244, and TIM3 identified as candidate immunotherapeutic targets at relapse.

• Molecular subgroup-specific unmet needs persist, including NPM1-mutated/KMT2A-rearranged AML (addressed by menin inhibitors revumenib and ziftomenib), FLT3-mutated disease (with resistance linked to PI3K/AKT and ERK/MAPK pathway activation, and open questions on optimal sequencing/combination with gilteritinib, midostaurin, and quizartinib), and IDH-mutated AML (ivosidenib, enasidenib).

• Diagnostic and monitoring limitations compound treatment challenges, as current immunophenotyping panels for diagnosis and measurable residual disease (MRD) detection primarily focus on blast identification, potentially overlooking broader AML heterogeneity relevant to relapse risk.

• Strategic gaps for future development include the need for deeper characterization of the immune microenvironment to prioritize therapeutic targets, personalized combination strategies, and expansion of the antibody-based treatment landscape — currently limited to gemtuzumab ozogamicin as the sole approved therapeutic antibody in AML.

Annamycin's Cardiotoxicity Profile: A Key Differentiator

Preclinical toxicity studies establish a favorable safety profile for liposomal Annamycin (L-Ann) relative to doxorubicin, with a strong emphasis on cardiac safety. In murine single-dose studies, free Annamycin was approximately twice as toxic as doxorubicin (LD50: 8.8 mg/kg vs. 19.9 mg/kg; P < 0.01), but liposomal encapsulation reduced Annamycin's toxicity by a further 2-fold (LD50: 15.74 mg/kg for L-Ann vs. 8.8 mg/kg for free Annamycin; P < 0.01). The dominant toxicity observed with Annamycin, whether free or liposome-incorporated, was granulocytopenia, which was notably more pronounced than with an equitoxic dose of doxorubicin, as confirmed by blood counts and pathological studies. Critically, chronic dosing studies in mice demonstrated that L-Ann was markedly less cardiotoxic than doxorubicin, with lower cumulative toxicity (assessed via body weight and mortality) following weekly administration of a fraction of the subacute LD10. These findings support the characterization of L-Ann as a selectively myelotoxic but noncardiotoxic anthracycline, distinguishing it from doxorubicin's well-known dose-limiting cardiotoxicity.

Beyond cardiotoxicity, L-Ann exhibited additional tolerability advantages, including reduced vesicant toxicity compared with doxorubicin following intradermal administration in mice. In large-animal studies, beagle dogs tolerated the mouse-equivalent LD10 dose of L-Ann (1.4 mg/kg) without adverse effects, hematological or biochemical abnormalities, or pathological changes, reinforcing the translatability of the favorable toxicity profile observed in rodent models. The liposomal carrier itself appears to play a central role in this improved safety margin, with formulation characteristics directly influencing toxicity outcomes: reducing liposome particle size from 1.6 to 0.03 microns halved Annamycin's subacute toxicity, while incorporation of phospholipids with a high phase transition temperature and GM1 into the liposome bilayer moderately increased subacute toxicity. These formulation-toxicity relationships underscore the importance of liposomal engineering in optimizing Annamycin's therapeutic index.

Collectively, these preclinical data positioned the submicron liposomal formulation of Annamycin as a candidate with a differentiated safety profile—particularly the absence of cardiotoxicity—supporting its advancement into Phase I clinical investigation. Notably, the available literature reviewed here addresses Annamycin's safety and tolerability in isolation; no comparative safety or tolerability data for cytarabine, nor head-to-head clinical data combining or contrasting Annamycin and cytarabine across studied indications, were identified in the source material.